Jianyang Hu

Jianyang Hu

Auto-generated profile, based on publicly available information

Jianyang Hu

Southern University of Science and Technology 1 Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine Shenzhen, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Phytomedicine
Verified
Journal Article
Closed access
JLJun-Shan Liu
Jun-Shan Liu
CHChu-Ying Huo
Chu-Ying Huo
HCHui-Hui Cao
Hui-Hui Cao
CFChun-Lin Fan
Chun-Lin Fan
JHJian-Yang Hu
Jian-Yang Hu
ZYZhiling Yu
Zhiling Yu

8 June 2026 in Cancer Discovery
Verified
Journal Article
Closed access
XLXuefei Liu
Xuefei Liu
JTJun Tan
Jun Tan
CWChun Wu
Chun Wu
GHGuanyin Huang
Guanyin Huang
YCYixin Cheng
Yixin Cheng
XHXIN HONG
XIN HONG
Brain metastasis remains a devastating disease with dismal prognosis. How circulating tumor cells (CTC) penetrate the blood–brain barrier (BBB) and reprogram the brain microenvironment remains unclear. Using spatially resolved multi-omics profiling of CTCs and brain metastases, integrated with experimental and clinical analyses, we identified glycoprotein nonmetastatic melanoma protein B (GPNMB) as a CTC-secreted driver of vascular disruption and brain colonization. CBX3 upregulation induced GPNMB expression, which bound endothelial EGFR, triggering CBL-mediated ubiquitination and degradation. Attenuated EGFR signaling suppressed FTO and disrupted endothelial junctions via YTHDF2-dependent TJP1 m6A methylation. Remarkably, GPNMB-induced BBB remodeling promoted immune infiltration via the CXCL12–CXCR4 axis and induced time-course–dependent T-cell exhaustion within the brain microenvironment. Clinically, elevated CBX3+GPNMB+ CTCs and plasma CXCL12 were significantly associated with brain metastasis progression in lung cancer and melanoma. Therapeutically, dual blockade of GPNMB and PD1 enhanced anti–brain metastasis efficacy in mice, unveiling GPNMB as a promising target for precision immunotherapy. Significance: GPNMB is a CTC-secreted driver of BBB disruption and brain colonization via the CBX3-GPNMB–EGFR–FTO–TJP1 axis. GPNMB-induced BBB remodeling promotes CXCL12–CXCR4-mediated immune infiltration and enhances T-cell exhaustion, sensitizing brain metastasis tumors to GPNMB/PD1 dual blockade. CBX3+GPNMB+ CTCs and plasma CXCL12 may serve as noninvasive biomarkers for brain metastasis management.

19 December 2025 in Cancer Research
Verified
Journal Article
Closed access
JHJianyang Hu
Jianyang Hu
BZBinyu Zhang
Binyu Zhang
JCJunhao Chen
Junhao Chen
GHGuanyin Huang
Guanyin Huang
MZMao Zhao
Mao Zhao
XHXIN HONG
XIN HONG
Tumor senescence is a critical mechanism underlying tumor progression and recurrence. A better understanding of how premetastatic circulating tumor cells (CTC) exploit senescence to survive in the bloodstream could help reveal vulnerabilities for therapeutic intervention. Using patient-derived melanoma CTC lines and xenograft models, we identified a role for the cytoskeletal regulator cortactin in mTOR/p53-dependent senescence. Cortactin localized to Rab7-positive endosomes and maintained late-endosomal homeostasis. Depletion of cortactin induced aberrant endosomal aggregates with mTOR accumulation and hyperactivation, subsequently leading to p53 activation, G0–G1 arrest, and cellular senescence. This oncogene-induced senescence was characterized by the induction of the senescence-associated secretory phenotype and β-galactosidase (SA-β-gal), loss of Ki-67 and lamin B1, and elevated mitochondrial reactive oxygen species (mtROS). Notably, a positive feedback loop between p53 and mtROS was essential for maintaining stable senescence in CTCs. Clinically, the proportion of SA-β-gal–positive senescent CTCs was significantly correlated with therapeutic resistance and disease progression in a prospective cohort of patients with melanoma. A sequential strategy using cortactin depletion followed by an anti–Bcl-xL senolytic eliminated the persistent CTCs and suppressed blood-borne metastasis. Thus, this study uncovered a unique senescent CTC subpopulation regulated by a cortactin/mTOR/p53/mtROS axis that can be targeted to suppress the metastatic progression of melanoma. Significance: The cytoskeleton regulator cortactin governs senescence induction and maintenance in melanoma circulating tumor cells, providing an axis that can be targeted by a sequential therapeutic strategy to block metastasis.

16 March 2026
Verified
Other
Open access
PDF file
JHJianyang Hu
Jianyang Hu
BZBinyu Zhang
Binyu Zhang
JCJunhao Chen
Junhao Chen
GHGuanyin Huang
Guanyin Huang
MZMao Zhao
Mao Zhao
XHXIN HONG
XIN HONG
Supplementary figure S2. CTTN KD in Mel-182-1 and PEM22 CTCs with BRAF mut/NRAS mut did not induce robust senescence

16 March 2026
Verified
Other
Open access
PDF file
JHJianyang Hu
Jianyang Hu
BZBinyu Zhang
Binyu Zhang
JCJunhao Chen
Junhao Chen
GHGuanyin Huang
Guanyin Huang
MZMao Zhao
Mao Zhao
XHXIN HONG
XIN HONG
Supplementary Table S3, primer, shRNA and siRNA sequences

16 March 2026
Verified
Other
Open access
PDF file
JHJianyang Hu
Jianyang Hu
BZBinyu Zhang
Binyu Zhang
JCJunhao Chen
Junhao Chen
GHGuanyin Huang
Guanyin Huang
MZMao Zhao
Mao Zhao
XHXIN HONG
XIN HONG
Supplementary figure S9. Candidate-based kinase screening identifies mTOR as the major upstream regulator of p53 pathway activation in CTTN-KD cells